CH3(CH2)18CH2
CH2 ( Three stereoisomers of a mycolic acid containing two cis-cyclopropanes, and two stereoisomers of a trans-cyclopropane containing mycolic acid are obtained by coupling single enantiomers of the three coloured fragments using the black carbon chains in multi-step sequences Mycolic acids (MA) from mycobacteria, having a general structure 1 (Figure 1 ), usually containing 70 to 90 carbons, are present as complex mixtures with varying chain lengths and a number of combinations of distal and proximal substituents X and Y, and different exact compositions depending on the species.
1-7

Figure 1 General structure of mycolic acids
Commonly, group Y is a cis-or α-methyl substituted trans-cyclopropane, a cis-alkene or a trans-alkene with an adjacent methyl substituent. Group X is a cis-cyclopropane (α-and α′-MA), a -CHMeCHOMe-fragment (methoxy-MA) or a -CHMeCO-fragment (keto-MA). Structural assignment has often been based on mass spectra of mixtures of homologues or fragments from them. 8, 9 It is often difficult from the early literature to judge the certainty with which a structure has been assigned or, indeed, which actual values of a-d have been determined. However, recent detailed studies have clarified the situation considerably. 8, 9 The presence and proportion of individual classes of MA, and in particular cyclopropanated MA, is known to be important for the virulence of diseases such as tuberculosis. [10] [11] [12] [13] The free MA are themselves strongly bioactive and indeed synthetic MA of different classes, matching the structures of components of natural mixtures, are selectively active. 14 Among the most abundant of these acids are α-MAs containing two cis-cyclopropanes (2) . 8, 9 The acid 2 (a = Indeed, such α-MA make up around 50% of the MA isolated from Mtb cells. 7 Although the hydroxy-acid grouping is known to be of R,R-configuration, the absolute stereochemistries of the cyclopropanes are not always clearly defined. There is evidence that the 1-methyl-2-methoxy unit at the distal position from the hydroxy acid in methoxy-MA is S,S, 16, 17 while the corresponding carbon bearing a methyl group in ketomycolates is also S. 18 Much is now known about the enzymes controlling the biosynthesis of MA, [19] [20] [21] [22] [23] and it has been proposed, for example, that the cis-cyclopropane unit, the α-methyl-trans-cyclopropane and the α-methyl-β-alkoxy unit are formed from a Z-alkene through a common intermediate (Scheme 1) . 24, 25 
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this would be that the three subunits should have a common absolute stereochemistry at the carbon bearing the methyl group and C-1 of the cis-cyclopropane.
Scheme 1 Proposed common formal intermediate cation in MA biosynthesis
The stereochemistry B of the trans-cyclopropane unit is consistent with NMR spectra and optical rotations of this fragment in methoxy-MA, 26 and with that of the distal position in methoxy-and keto-MA, and on this basis the ciscyclopropane stereochemistry is likely to be A. However, there is little direct evidence that this is the case, and an alternative possibility is that the cis-isomer is produced with an alternative stereochemistry in the enzyme-promoted cyclopropanation, or indeed that a mixture of stereoisomers is produced. Although the isomer with stereochemistry A at both cyclopropanes, compound 2a ( Figure 3 ) was reported some time ago , 27,28 and has been shown to have significant biological activity in a number of contexts, 14, 29 we now describe the synthesis of the three other stereoisomers of 2 containing two cis-cyclopropanes in order that their biological properties may be compared to those of 2a.
Figure 3 First synthetic α-mycolic acid
The synthetic method used, a simple extension of the method used to prepare 2a, involved the use of a common precursor for the two chiral cyclopropane units, with C-C bonds being created at the positions shown in Figure 4 .
The (1S,2R)-aldehyde 3 was prepared by a method described earlier from (1S,2R)-butyryloxymethyl-2-formylcyclopropane. 28, 30, 31 Reaction of (1R)-butyryloxymethyl-(2S)-formyl-cyclopropane 5 with sulfone 4 in a similar way (Scheme 2) led to the (1R,2S)-aldehyde 6.
Scheme 2 Reagents and conditions: (i) 4, LiHMDS, THF (80%); (ii) LiAlH 4 , THF (90%); (iii) N 2 H 4 , NaIO 4 , AcOH, CuSO 4 , i PrOH (83%); (iv) PCC, CH 2 Cl 2 (90%).
The aldehyde 6 was homologated to give 8 by reaction with sulfone 7 and base, again to give a mixture of E-and Zalkenes, followed by reduction to the corresponding alcohols, hydrogenation of the alkenes using di-imide, and then oxidation to the aldehyde 9, or converted into the sulfone 10 (Scheme 3). The proximal cyclopropane unit 11 32, 33 was treated with aldehyde 9 in a modified Julia reaction, 21 to give a 1:1 mixture of E-and Z-alkenes. Reduction of the esters to the corresponding alcohols using lithium aluminium hydride, followed by hydrogenation of the alkene, again using di-imide, gave a single enantiomer of alcohol 12 (Scheme 4). C NMR spectra of all four acids were essentially identical to those of a sample extracted from M. tuberculosis. The natural mixture was protected as the acetate on the alcohol and a methyl ester ([α] D +3.7), 27 as a mixture of homologues in which 2 predominates. The specific rotation of the synthetic material 2a, protected in the same way ([α] D +4.2) was close to that of the natural mixture. The specific rotation of the synthetic free acid 2a was [α] D +2.1; the rotation is dominated by the chirality of the hydroxy acid part of the molecule and not indicative of the chirality of the cis-cyclopropanes, which contribute very little. Thus, the three isomers prepared in this work showed specific rotations of +2.0 (22), +2.5 (23) and +2.5 (24) .
MA containing trans-cyclopropanes at the position in the chain closest to the hydroxy-acid are reported to have a particular effect on the cell wall and therefore on the sensitivity of mycobacterial species to hydrophobic antibiotics. 5 A purified trehalose ester of MA lacking trans-cyclopropane rings is five times more potent in stimulating macrophages, and is important as a suppressor of Mtb induced inflammation and virulence. 10 The biosynthesis apparently involves conversion of a cis-alkene into an α-methyl-trans-alkene caused by MmaS1 and SAM. This is then cyclopropanated by the CmaA2 gene, again with SAM, to give the α-methyltrans-cyclopropane. [21] [22] [23] [24] [25] Inactivation of CmaA2 causes the accumulation of unsaturated derivatives in both methoxyand keto-MA and the lack of trans-cyclopropanes. 26 Although α-MA containing a proximal trans-cyclopropane and a distal cis-cyclopropane do not appear to be present in Mtb, they are present in other Mycobacteria such as Mycobacterium kansasii and Mycobacterium avium complex. 
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We therefore describe the synthesis of two stereoisomers of one such compound. The aldehyde 25 28 was coupled to sulfone 27 (see the Supporting Information) in a modified Julia-Kocienski reaction, followed by saturation of the derived mixture of alkenes with di-imide to give 28, and then oxidative cleavage of the acetal to produce the cisaldehyde 29. Treatment with base isomerised this to the trans-cyclopropane aldehyde 30. The corresponding aldehyde 31 was prepared by a similar sequence (Scheme 9). Chain extension of the two aldehydes by standard methods provided the aldehydes 33 and 34 (Scheme 10), which were then coupled to sulfone 35 35 to provide, after hydrolysis of the protecting groups, the free MA 37 and 38 (Scheme 11). The effects of the four stereoisomeric MAs 2a and 22-24 in stimulating T-cells have recently been reported. Rather surprisingly, mycolic acid 24 is somewhat more stimulatory than 2a, both having a somewhat stronger effect than 22, with 23 having the least effect. 36 The trans-cyclopropane 38 is moderately stimulatory, while 37 has a smaller effect.
MA are present both as bound tetramycolyl penta-arabinose clusters and as extractable trehalose 6,6′-dimycolates ('cord factor'). [2] [3] [4] [5] [6] [7] The MA 37 and 38 were converted into the corresponding TDM and TMM (see the the Supporting Information) using methods described before. 37 The effects of the resulting TDMs and TMMs, and those derived from acid 22 in activating bone marrow dendritic cells to produce proinflammatory cytokines (IL-6 and TNF-α) and reactive oxygen species has recently been reported. 38 Moreover, they are recognised by antibodies in the serum of patients with pulmonary tuberculosis, providing the basis of a diagnostic assay. 39 Chemicals used were obtained from commercial suppliers or prepared from them by methods described. Solvents which had to be dry, for example diethyl ether and tetrahydrofuran were dried over sodium wire. Petroleum was of boiling point 40-60 °C. Reactions under inert conditions were carried out under a slow stream of nitrogen. Reactions carried out at low temperatures were cooled using a bath of methylated spirit with liquid nitrogen. Silica gel (Merck 7736 silica gel) and silica plates used for thin-layer and column chromatography were obtained from Aldrich. Organic solutions were dried over anhydrous magnesium sulfate. IR spectra were carried out with a PerkinElmer 1600 FTIR spectrometer as liquid films. NMR spectroscopy was carried out with Bruker Avance 400 or 500 spectrometers. [ 28 were dissolved in anhydrous THF (250 mL) and cooled to -10 °C. LiHMDS (38.6 mL, 0.041 mol) was carefully added and the mixture was stirred for 1.5 h, then water (100 mL) was added. The aqueous layer was separated and extracted with petrol/ether (1:1, 3 × 50 mL) and the combined organic layers were washed with brine (2 × 100 mL), dried and evaporated to obtain a residue; column chromatography, eluting with petrol/EtOAc (20:1) gave butyric acid (E/Z)-(1R,2S)-cis-2-eicos-1-enylcyclopropyl-methyl ester (9.5 g, 80 %) a colourless oil, as a mixture of isomers in ratio 2.5:1. The derived ester (8.5 g, 0.020 mol) in THF (50 mL) was gradually added to a stirred suspension of lithium aluminium hydride (1.3 g, 0.034 mol) in THF (50 mL) placed in a cooling bath, in order to control the exothermic reaction. The reaction was heated at reflux at 100 °C for 2 h, then cooled and quenched with freshly prepared sat. aq. sodium sulfate decahydrate (30 mL), stirred until a white precipitate was formed and then filtered through a bed of Celite washing with THF (3 × 50 mL). The filtrate was evaporated and the crude product was purified by column chromatography eluting with petrol/EtOAc (5:2) to give (E/Z)-(1R,2S)-cis-2-eicos-1-enylcyclo-propylmethanol (6.4 g, 90%) as a thick colourless oil. Hydrazine hydrate (80 mL), glacial acetic acid (5 mL) and sat. aq. copper sulphate (5 mL) were added in succession to the above alkenes (6.0 g, 0.017 mol) in 2-propanol (200 mL) at 70-80 °C. Subsequently, sodium (meta)periodate (73.4 g, 0.343 mol) in hot water was added dropwise over a period of 2 h, maintaining the temperature at 70-80 °C. The reaction was stirred for 1 h at r.t. and then quenched with sat. aq. ammonium chloride (100 mL). The aqueous layer was extracted with petrol/EtOAc (1:1, 3 × 150 mL) and the combined organic layers were washed with brine, dried and evaporated, and the product was recrystallised from petrol to give (1R,2S)-2-eicosylcyclpropyl methanol. (c) The above alcohol (5.0 g, 14 mmol) in dichloromethane (80 mL) was added to a stirred suspension of pyridinium chlorochromate (7.6 g, 35 mmol, 2.5 mol equiv) in dichloromethane (200 mL) at r.t. The mixture was stirred for 2 h at r.t., then diluted with ether/petrol 2:1 (300 mL), then filtered through a pad of silica and Celite, washed well with ether (2 × 100 mL) and evaporated to give a white solid, which was purified by column chromatography on silica eluting with petrol/ether 2:1 to give the title compound 6. 
Yield
13-((1R,2S)-cis-2-Eicosylcyclopropyl)tridecan-1-ol (8)
LiHMDS (18.2 mL, 19.3 mmol) was added to a stirred solution of (1R,2S)-2-eicosylcyclopropanecarbaldehyde 6 (4.0 g, 11 mmol) and 2,2-dimethylpropanoic acid 12-(1-phenyl-1H-tetrazole-5-yl-sulfonyl)dodecyl ester 7 (7.10 g, 14.9 mmol) 40 in anhydrous THF (200 mL) at -10 °C under nitrogen. The mixture was allowed to reach r.t., stirred for 2 h, then the reaction was quenched with sat. aq. ammonium chloride (200 mL), the aqueous layer was separated and extracted with petrol/ether (1:1, 3 × 200 mL). The combined organic layers were dried and concentrated and the residue was purified by column chromatography, eluting with petrol/ether (20:1) to give 2,2-dimethylpropionic acid (E/Z)-13-((1R,2S)-cis-2-eicosylcyclopropyl)tridec-12-enyl ester (6.6 g, 98%) as a white solid, as a mixture of isomers in ratio (2.8 :1). The derived ester (6.0 g, 10 mmol) in THF (20 mL) was gradually added to a stirred suspension of lithium aluminium hydride (0.77 g, 20 mmol) in THF (50 mL) at 0 °C. The mixture was heated at reflux at 100 °C for 2 h, then worked up and purified as before to give (E/Z)-13-((1R,2S)-cis-2-eicoscylcyclopropyl)-tridec-12-en-1-ol (5.0 g, 91%) as a white solid. Hydrazine monohydrate (20 mL), acetic acid (2 mL), and sat. aq. copper sulfate (2 mL) were added in succession to the derived alcohols (5.0 g, 9.7 mmol) in isopropanol (250 mL) at 80 °C, and then sodium metaperiodate solution (20 g, 97 mmol) in hot water (60 mL) was carefully added dropwise, maintaining the temperature at 80 °C, then worked up as above. The product was recrystallised from chloroform to give the title compound 8. 
13-((1R,2S)-2-Eicosylcyclopropyl)tridecanal (9)
Alcohol 8 (4.5 g, 8.6 mmol) in dichloromethane (80 mL) was added to a stirred suspension of PCC (4.66 g, 22.0 mmol, 2.5 mol equiv) in dichloromethane (60 mL) in portions at r.t. The mixture was stirred for 2 h and then diluted with petrol/ether 2:1 (300 mL), filtered through a pad of Celite on silica, then washed well with warm ether (400 mL) and the filtrate was evaporated to give a residue. This was purified by column chromatography on silica eluting with petrol/ether 2:1 to give the title compound 9.
Yield: 3. 
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5-[13-((1R,2S)-cis-2-Eicosylcyclopropyl)tridec-ane-1-sulfonyl]-phenyl-1H-tetrazole (10)
(a) 13-((1R,2S)-cis-2-Eicosylcyclopropyl)tridecan-1-ol 8 (4.0 g, 7.7 mmol) was dissolved in anhydrous THF (10 mL) together with triphenylphosphine (2.6 g, 10 mmol) and 1-phenyl-1H-tetrazole-5-thiol (1.8 g, 10 mmol). The mixture was cooled to 0 °C, followed by the addition of DEAD (1.7 mL, 10 mmol) in anhydrous THF (5 mL). The mixture was stirred overnight at r.t., evaporated, then the residue was washed with petrol/ether (10:1) and then filtered. The filtrate was evaporated and the product was purified by column chromatography eluting with chloroform to give 5-[13-((1R,2S)-cis-2-eicosylcyclopropyl)tridecyl-sulfanyl]phenyl-1H-tetrazole. (b) Sodium hydrogen carbonate (1.7 g, 20 mmol) was added to a stirred solution of the above tetrazole (3.0 g, 4.4 mmol) in dichloromethane (50 mL), followed by the addition of a mixture of anhydrous 3-chloroperoxybenzoic acid (2.0 g, 88 mmol) and dichloromethane (50 mL). The reaction was stirred at r.t. for 18 h to give an off-white precipitate, then aq. sodium hydroxide (5%; 100 mL) was added and the mixture was stirred for 2 h. The organic layer was separated and the aqueous layer was extracted with dichloromethane (3 × 200 mL). The combined organic layers were washed with water (2 × 200 mL), dried and evaporated. The product was recrystallised from methanol/acetone (1:1), which gave a white solid of the title compound 10. 
Yield
((1R,2S)-2-(14-((1R,2S)-2-Eicosylcyclopropyl)tetradecyl)cyclopropyl)methanol (12)
(a) LiHMDS (12.8 mL, 13 mmol, 1.06 M, 1.5 mol) was added dropwise with stirring to aldehyde 9 (3.6 g, 6.9 mmol) and sulfone 11 (3.3 g, 7.5 mmol) 32, 33 in anhydrous THF (30 mL) under nitrogen at-10 to -4 °C. The mixture was allowed to reach r.t., stirred for 5 h, then the reaction was quenched with sat. aq. ammonium chloride (50 mL) and petrol/ether 1:1 (100 mL). The organic layer was separated and the aqueous layer was re-extracted with petrol/ether 1:1 (2 × 100 mL). The combined organic layers were dried and evaporated to give a solid; column chromatography on silica eluting with petrol/ether 10:1 gave a mixture of alkenes (3.0 g, 65 %).
(b) LiAlH 4 (0.2 g) was added to stirred THF (100 mL) at 0 °C under nitrogen to ensure THF dryness. Then further LiAlH 4 (1.0 g, 26 mmol) was added. A solution of alkenes (3.0 g, 4.5 mmol) in anhydrous THF (20 mL) was added dropwise by using a syringe at 0 °C and the mixture was heated at reflux for 3 h, then cooled to 0 °C and the reaction was quenched with sat. aq. sodium sulphate decahydrate (20 mL), which was added dropwise and stirred at r.t until a white precipitate was formed followed by addition of MgSO 4 (20 g ). THF (40 mL) was added and the mixture was filtered through a pad of silica, dried and the solvent evaporated to give a mixture of alcohols (2.4 g, 89%), which was used for the next step without further purification.
(c) Sodium (meta)periodate (20.3 g, 95.0 mmol) in hot water (50 mL) was added over 70 min at 70-80 °C to a stirred solution of above alcohol (2.9 g, 4.8 mmol) in isopropyl alcohol (250 mL), acetic acid (1.5 mL), sat. aq. copper sulphate (1.5 mL) and hydrazine hydrate (20 mL). The mixture was stirred for 2 h until it reached r.t., then diluted with water (100 mL) and petrol/ether 5:1 (400 mL). Due to the low solubility of the product, the mixture was warmed (40 °C) to allow separation. The aqueous layer was re-extracted with warm petrol/ether 5:1 (3 × 100 mL). The combined organic layers were dried and evaporated to give a solid. Column chromatography on silica eluting with petrol/ether 5:1 gave the title compound 12. 
(1S,2R)-2-[14-((1R,2S)-2-Eicosylcyclopropyl)tetradecyl]cyclopropyl Methanol (14)
LiHMDS (3.7 mL, 4.0 mmol) was added to a stirred solution of butyric acid (1S,2R)-(cis-2-formylcyclopropyl)methyl ester 13 (0.5 g 3.0 mmol) and sulfone 10 (2.1 g, 30 mmol) in anhydrous THF (30 mL) at -10 °C. The mixture was allowed to reach r.t. and stirring was continued for 1.5 h, then worked up and purified as before to give butyric acid 2 g, 62%) as a white solid as a mixture in ratio 2.5:1. The above ester (1.2 g, 1.8 mmol) in THF (10 mL) was added dropwise to a stirred suspension of lithium aluminium hydride (0.14 g, 3.7 mmol) in THF (10 mL) at -10 °C under nitrogen atmosphere. The reaction was heated at reflux at 100 °C for 2.5 h then worked up as before to give (1S,2R)-2-[(E/Z)-14-((1R,2S)-2-eicosylcyclopropyl)tetradec-1-enyl]cyclopropyl methanol (0.77 g, 72 %) as a white solid. Hydrazine monohydrate (7 mL), acetic acid (1 mL), and sat. aq. copper sulfate (1 mL) were added in succession at 70-80 °C to a stirred solution of the above alcohol (0.77 g, 1.3 mmol) in isopropyl alcohol (50 mL). Still maintaining the temperature at 80 °C, a solution of sodium metaperiodate (2.8 g, 13 mmol) in hot water (10 mL) was carefully added dropwise. The mixture was allowed to reach r.t. and stirred for 1 h, then worked up as above to give the title compound 14. 
5-(((1R,2S)-2-(14-((1R,2S)-2-Eicosylcyclopropyl)tetradecyl)cyclopropyl)methylsulfonyl)-1-phenyl-1H-tetrazole (17)
(a) Alcohol 12 (1.7 g, 2.9 mmol) was dissolved in anhydrous THF (50 mL) together with triphenylphosphine (1.14 g, 4.3 mmol, 1.5 equiv) and 1-phenyl-1H-tetrazole-5-thiol (0.82 g, 4.6 mmol, 1.6 equiv). The mixture was cooled to 0 °C, followed by the addition of DEAD (0.82 g, 4.0 mmol, 1.4 equiv) in anhydrous THF (5 mL). The mixture was stirred at r.t. overnight. The solvent was evaporated to a small volume to which petrol/ether 1:1 (100 mL) was added and the mixture was stirred at r.t. for 45 min, then filtered. The filtrate was dried and evaporated to give a solid. Column chromatography on silica eluting with petrol/ether 10:2 gave 5- (b) Sodium hydrogen carbonate (1.03 g, 12 mmol, 4.5 equiv) was added to a stirred solution of the above tetrazole (2.0 g, 2.7 mmol) in dichloromethane (100 mL), followed by the addition of a mixture of anhydrous 3-chloroperoxybenzoic acid 70% (1.67 g, 9.7 mmol, 2.5 equiv) in CH 2 Cl 2 (50 mL). The reaction was stirred at r.t. for 48 h to give an off-white precipitate. Aq. sodium hydroxide (5%, 80 mL) was added and the aqueous layer was extracted with dichloromethane (3 × 200 mL). The combined organic layers were washed with water (2 × 200 mL), dried and evaporated. The product was recrystallised from methanol/acetone (1:1), to give the title compound 17. 
5-[(1S,2R)-2-[14-((1R,2S)-2-Eicosylcyclopropyl)tetradecyl]cyclopropylmethanesulfonyl]-1-phenyl-1H-tetrazole (18)
(a) Alcohol 14 (0.55 g, 0.85 mmol) was dissolved in anhydrous THF (5 mL) and then triphenylphosphine (0.30 g, 1.1 mmol) and 1-phenyl-1H-tetrazole-5-thiol (0.2 g, 1.1 mmol) were added. The mixture was cooled to 0 °C and treated as above with DEAD (0.18 mL, 1.1 mmol) in anhydrous THF (5 mL). After stirring at r.t. overnight, the reaction mixture was worked up as above. Column chromatography eluting with dichloromethane 
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molybdate(VI) tetrahydrate (1.20 g, 0.94 mmol) in cold hydrogen peroxide (5 mL) was added. The reaction was stirred for 18 h and then poured into water (200 mL) and extracted with dichloromethane (3 × 50 mL). The organic layers were washed with water (2 × 50 mL) and concentrated. Column chromatography eluting with petrol/ether (5:2) gave the title compound 18. .
Yield
5-[(1R,2S)-2-[14-((1S,2R)-2-Eicosylcyclopropyl)tetradecyl]cyclopropylmethanesulfonyl]-1-phenyl-1H-tetrazole (19)
(a) Alcohol 16 (0.70 g, 1.2 mmol) was dissolved in anhydrous THF (5 mL) together with triphenylphosphine (0.41 g) and 1-phenyl-1H-tetrazole-5-thiol (0.28 g, 1.55 mmol). The mixture was cooled to 0 °C, followed by the addition of DEAD (0.24 mL, 1.55 mmol) in anhydrous THF (5 mL), and then stirred overnight at r.t. Work up as above followed by column chromatography eluting with dichloromethane gave the sulfane. 2-((R)-1-(tert-Butyldimethylsilanyloxy)-12-{(1R,2S)-2-[14-((1R,2S)-2-eicosylcyclopropyl) tetradecyl]cyclopropyl}do-decyl)hexacosanoic Acid Methyl Ester (21) (a) LiHMDS (2.78 mL, 2.9 mmol, 1.3 mol equiv, 1.06 M) was added to a stirred solution of sulfone 17 (1.77 g, 2.27 mmol) and aldehyde 20 (1.77 g, 2.5 mmol, 1.1 mol equiv) in anhydrous THF (40 mL) at -10 °C under nitrogen. The solution was allowed to reach r.t., stirred for 2 h, then petrol/ether 10:1 (100 mL) and sat. aq. NH 4 Cl (50 mL) were added. The organic layer was separated and the aqueous layer was reextracted with petrol/ether 10:1 (2 × 100 mL). The combined organic layers were dried and evaporated. Column chromatography eluting with petrol/ether 20:1 gave the product alkenes (2.5 g, 87%) as an E/Zmixture in ratio 2.5:1.
(b) Dipotassium azodicarboxylate (3.0 g, 0.015 mol) was added to a stirred solution of the above alkenes (2.4 g, 1.9 mmol) in anhydrous THF (20 mL) and MeOH (25 mL) and then cooled to 0 °C. Then acetic acid (5 mL) in THF (5 mL) was added dropwise at a rate of 1 mL/15 min. The reaction turned bright-yellow and was left stirring for 9 h at 5 °C. The procedure was repeated as above with further dipotassium azodicarboxylate, acetic acid, stirring for a further 9 h, then quenched by adding the mixture in small portions to sat. aq. NaHCO 3 (50 mL). After extraction, column chromatography eluting with petrol/ether 20:1 gave the title compound 21. 
(R)-2-((R)-1-Hydroxy-12-{(1R,2S)-2-[14-((1R,2S)-2-eicosylcyclopropyl)tetradecyl]cyclopropyl}dodecyl)hexacosanoic Acid (22)
(a) A dry polyethylene vial equipped with an acid-resistant rubber septum was charged with the above TBDMS methyl ester (1.9 g, 1.5 mmol) and anhydrous pyridine (2 mL) in anhydrous THF (25 mL) and stirred at r.t. under argon. To it was added hydrogen fluoride-pyridine complex as ca. 70% hydrogen fluoride (3 mL) at 5 °C. The mixture was then stirred at 45 °C for 17 h. The mixture was diluted with petrol/ether 10:1 (100 mL) and neutralised by pouring it slowly into sat. aq. sodium bicarbonate until no more CO 2 was liberated. The product was extracted with warm petrol/ether 10:1 (2 × 100 mL), and the combined organic layers were washed with brine (100 mL). The organic layer was dried and evaporated to give a residue, which was purified by chromatography eluting with petrol/ether 10: (b) The above methyl ester (1.0 g, 0.9 mmol) was dissolved in THF (15 mL), MeOH (1 mL) and water (1.5 mL), and then lithium hydroxide monohydrate (1.10 g, 26.2 mmol, 30 equiv) was added to the stirred mixture at r.t. The reaction was heated at 45 °C for 18 h, then cooled to r.t. and diluted with petrol/EtOAc (7:2, 100 mL), followed by the dropwise addition of sat. aq. potassium hydrogen sulfate (20 mL), which brought the mixture to pH 1. The aqueous layer was separated and re-extracted with warm petrol/EtOAc (7:2, 3 × 100 mL). The combined organic layers were dried and concentrated to give a crude product, which was purified by column chromatography, eluting with warm petrol/EtOAc (7:2) to give compound 22. (b) Dipotassium azodicarboxylate (2.0 g, 10 mmol) was added to a stirred solution of the derived esters (0.11 g, 0.09 mmol) in anhydrous THF (3 mL) and MeOH (1.5 mL) and then cooled to 0 °C under nitrogen. Glacial acetic acid (0.5 mL) was dissolved in THF (1.0 mL), and then added dropwise to the reaction mixture, which was stirred overnight at r.t. The process was repeated using the same amount of glacial acetic acid in THF until there was a change in colour from bright yellow to off-white. Work up as above gave a very thick oil of the corresponding TBDMS methyl ester. (d) The above methyl ester (0.030 g, 0.026 mmol) was dissolved in THF (4.0 mL), MeOH (0.5 mL) and water (0.7 mL), and then lithium hydroxide monohydrate (0.02 g, 0.48 mmol) was added to the stirred mixture at r.t. The mixture was heated at 45 °C for 18 h, then cooled to r.t. and diluted with petrol/EtOAc (7:2, 5 mL), followed by the dropwise addition of sat. aq. potassium hydrogen sulfate (10 mL) to pH 1. The aqueous layer was extracted with warm petrol/EtOAc (7:2, 3 × 10 mL). The combined organic layers were dried and concentrated. Column chromatography, eluting with petrol/EtOAc (7:2) gave the title compound 23. 
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(b) Dipotassium azodicarboxylate (2.0 g, 10.3 mmol) was added to a stirred solution of the derived alkenes (0.11 g, 0.09 mmol) in anhydrous THF (3 mL) and MeOH (1.5 mL) and then cooled to 0 °C under nitrogen. Glacial acetic acid (0.5 mL) was dissolved in THF (1.0 mL), and then added dropwise to the mixture, which was stirred overnight at r.t. The process was repeated using the same amount of glacial acetic acid in THF until there was a change in colour from bright yellow to off-white. The reaction was worked up and purified as before to give (R) 
5-((S)-3-((1R,2R)-2-((S
)
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((1S,2R)-2-octadecylcyclopropyl)hexa-dec-3-en-2-yl)]cyclopropyl)-1,3-dioxolane (4.6 g, 78%) as a colourless oil. Dipotassium azodicarboxylate (4.5 g, 23.2 mmol) was added to a stirred solution of the above [1, 3] -dioxolane (4.6 g, 7.0 mmol) in THF (40 mL) and MeOH (15 mL) under nitrogen at 10 °C. A solution of glacial acetic acid (6 mL) and THF (6 mL) was added dropwise for 24 h then additional dipotassium azodicarboxylate (2.3 g, 11.6 mmol) and a solution of glacial acetic acid (3 mL) and THF (3 mL) were added and stirred for a further 24 h. The reaction was worked up as above to give the title compound 28. 
cis-(1R,2R)-2-((S)-16-((1S,2R)-2-Octadecylcyclopropyl)hexadecane-2-yl)cyclopropanecarbaldehyde (29)
Periodic acid (3.3 g, 17.1 mmol) was added to stirred solution of the acetal 28 (3.8 g, 5.8 mmol) in anhydrous ether (60 mL) under nitrogen at r.t. The mixture was stirred for 16 h, then worked up as above to give the aldehyde 29. 
Yield
trans-(1S,2R)-2-((S)-16-((1S,2R)-2-Octadecylcyclopropyl)hexadecan-2-yl)cyclopropanecarbaldehyde (30)
Sodium methoxide (0.60 g, 11 mmol) was added to a stirred solution of cis-aldehyde 29 (3.5 g, 6.0 mmol) in MeOH (20 mL) and THF (30 mL) and heated at reflux for 56 h. The mixture was cooled to r.t. and worked up as above to give the trans-aldehyde 30. 
16-((1S,2R)-2-((S)-16-((1S,2R)-2-Octadecylcyclopropyl)hexadecan-2-yl)cyclopropyl)hexadecanal (33)
(a) LiHMDS (6.8 mL, 7.2 mmol, 1.06 M) was added dropwise to a stirred solution of trans-aldehyde 30 (2.7 g, 4.6 mmol) and 15-(1-phenyl-1H-tetrazol-5-ylsulfonyl)pentadecyl pivalate 32 (2.5 g, 4.8 mmol) in anhydrous THF (30 mL) under nitrogen at -10 °C. The mixture was allowed to reach r.t. and stirred for 2 h, then worked up as above to give a thick oil, which solidified later as a mixture of (E/Z)-16-((1S,2R)-2-((S)-16-((1S,2R)-2-octadecylcyclopropyl)hexadec-ane-2-yl)cyclopropyl)hexadec-15-enyl pivalates (3.8 g, 94%). Dipotassium azodicarboxylate (4.5 g, 23 mmol) was added to a stirred solution of the above alkene (3.8 g, 4.3 mmol) in THF (30 mL) and MeOH (15 mL) under nitrogen at 10 °C. A solution of glacial acetic acid (6 mL) and THF (6 mL) was added dropwise for 24 h then additional dipotassium azodicarboxylate (2.3 g, 11.6 mmol) and a solution of glacial acetic acid (3 mL) and THF (3 mL) were added and stirred for a further 24 h. The reaction was worked up as above to give 16-((1S,2R)-2-((S)-16-((1S,2R)-2-octadecylcyclopropyl)hexadecane-2-yl)cyclopropyl)hexadecyl pivalate. (c) The above alcohol (1.50 g, 1.9 mmol) was dissolved in hot CH 2 Cl 2 (20 mL) and added to a refluxing stirred suspension of PCC (0.94 g, 4.4 mmol) in CH 2 Cl 2 (40 mL). The mixture was stirred vigorously for 2 h, then worked up as above to give aldehyde 33. (b) Lithium hydroxide monohydrate (0.38 g, 9.1 mmol) was added to a stirred solution of the above methyl ester (0.73 g, 0.61 mmol) in THF (12 mL), MeOH (1.5 mL) and water (2 mL) at r.t. The mixture was stirred at 45-50 °C for 18 h, then cooled to r.t. and quenched with sat. aq. NH 4 Cl (15 mL) then acidified to pH 1 with 5 % HCl and the product was extracted with petroleum/EtOAc (5:1, 3 × 30 mL). The combined organic layers were washed with water (20 mL), dried and evaporated. Column chromatography eluting with petroleum/EtOAc (7:2) gave the title acid 38. 
